ALTSTATION.IO

Labcorp Holdings Inc. (LH) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$275.16

Change

-1.10%

Market Cap

$22.87B

Avg Volume

780.9K

Company Overview

Labcorp Holdings Inc. provides a wide array of laboratory services, primarily through its Diagnostics Laboratories and Biopharma Laboratory Services segments. They offer numerous tests covering blood chemistry, urinalysis, genetics, infectious diseases, and drug monitoring, among others. Their clientele includes pharmaceutical companies, medical device and diagnostics firms, managed care organizations, hospitals, and individual patients. Based in Burlington, North Carolina, Labcorp has positioned itself as a critical player in the healthcare sector.

Labcorp is a market leader in diagnostics, holding a significant share of the laboratory testing services market. They benefit from a comprehensive service offering that combines routine and specialized testing, which differentiates them from smaller competitors. However, they face threats from rapid advancements in technology and growing competition from companies like Quest Diagnostics and Siemens Healthineers that focus on innovation and cost efficiency. Market dynamics such as the push for value-based care and increased demand for personalized medicine also affect their competitive positioning.

Currently, Labcorp is on a growth trajectory, emphasizing strategic pivots into specialty testing and digital healthcare solutions. Recent milestones include increased investment in technology to enhance their online platforms and patient experience. Additionally, they’ve expanded partnerships with biotech firms to support drug development, which underscores their commitment to adapting in a rapidly changing healthcare landscape. Overall, Labcorp is well-positioned to capitalize on emerging trends in diagnostics.

Key Financials

Market Cap

$22.87B

Revenue

$13.77B

EBITDA

$1.96B

Gross Margin

28.4%

Profit Margin

6.2%

Revenue Growth

8.6%

Total Cash

$598.10M

Total Debt

$6.58B

Free Cash Flow

$1.12B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

27.03

Forward P/E

15.72

Beta

1.00

52-Week High

$293.72

52-Week Low

$209.38

EPS

$10.18

50-Day Avg

$262.17

200-Day Avg

$262.26

Price/Book

2.63

Technical Analysis

The overall trend for Labcorp Holdings Inc. (LH) over the past 52 weeks shows a moderate upward trajectory, marked by a 14.4% increase, indicating ongoing bullish sentiment. Key support is evident around the $240 level, where the price bounced multiple times, while notable resistance is indicated around $277.2, where recent peaks have occurred. The price chart exhibits a series of higher lows and higher highs, contributing to a bullish flag pattern, which suggests potential for further upward movement if resistance is broken. Recently, the momentum has strengthened, particularly in the past few weeks as the current price, at $275.16, edges closer to the $277.2 resistance level, reflecting trader optimism. This current price sits near the upper end of its 52-week range, which implies a strong likelihood of testing or breaking through the resistance if the bullish trend continues, attracting additional buying interest.

Recent News and Developments

Here are the latest news and developments for Labcorp Holdings Inc

(LH) stock from January 31, 2026, to February 7, 2026:

1. Labcorp Enhances Liquidity with Expanded Receivables Facility

Labcorp Holdings recently executed a second amendment to its receivables purchase agreement, extending the facility’s termination date to January 26, 2029. This amendment also includes an “accordion feature” that can increase the facility’s size from US$700 million to US$825 million, providing Labcorp with additional liquidity flexibility and room to support working capital without immediately relying on on-balance-sheet debt. This strategic move aims to ease liquidity pressure and offers more financial flexibility, although the company’s existing high leverage and capital allocation priorities remain central risks for investors.

2. Upcoming Fourth Quarter 2025 Earnings Release Announced

Labcorp Holdings Inc. is scheduled to release its financial results for the fourth quarter of 2025 before the market opens on Tuesday, February 17, 2026. The company will host a conference call and webcast on the same day at 9 a.m. ET to discuss these results. Investors are keenly anticipating these earnings, as previous quarters have seen Labcorp surpass analyst consensus estimates.

Market Sentiment and Analyst Recommendations

Bull Case

Labcorp is firing on multiple cylinders right now. Revenue growth of 8.6% is solid for a mature diagnostic services company, and the 14.4% stock gain over 52 weeks shows the market is rewarding execution. The Roche collaboration on automated mass spectrometry is a legitimate competitive advantage — it improves throughput and margins while competitors scramble to keep up. Management just expanded the receivables facility to $825 million, which means they’re not desperate for cash and can fund growth without dilution. The analyst consensus is genuinely bullish: 17 analysts covering the stock, 81% with buy ratings, and a $300 target price implies 9% upside from current levels. With a P/E of 27, Labcorp is trading at a reasonable premium for a company with predictable cash flows and recurring revenue from lab testing. The stock is bumping up against $277 resistance, and breaking through that opens a run toward the $293 52-week high.

Bear Case

The debt load is the real problem here. Labcorp is carrying $6.58 billion in total debt against only $598 million in cash — a 11-to-1 ratio that limits financial flexibility and makes the company vulnerable if margins compress. The P/E of 27 is expensive for a business growing at 8.6%, leaving little room for disappointment. Quest Diagnostics and smaller regional labs are constant competitive threats, and healthcare reimbursement rates keep getting squeezed by payers. The company’s working capital story requires constant management of receivables, and that accordion feature on the facility is a band-aid, not a solution. Earnings on February 17 could easily disappoint after a strong run, especially if management guides down on 2026 growth. At the upper end of the 52-week range, the stock has limited margin of safety if macro conditions deteriorate or if the lab testing market softens.

What to Watch

The February 17 earnings call is the immediate catalyst. Focus on whether management maintains the 8.6% growth guidance or pulls it down — that will set the tone for the next quarter. Watch the gross margin numbers closely; if automation investments from the Roche deal aren’t translating into margin expansion, the bull thesis cracks. Track the debt-to-EBITDA ratio over the next two quarters; if it stays above 3.5x, refinancing costs could become a headwind. The $277.20 resistance level is critical on the chart — a clean break above it targets $293, but a rejection signals consolidation or pullback. Monitor competitive pricing pressure from Quest and regional labs in earnings commentary; any mention of pricing pressure should trigger caution. Finally, keep an eye on healthcare policy changes regarding reimbursement rates for lab testing, as any negative shifts could impact the entire sector’s margins.

Analyst Consensus

BUY

Based on 17 analyst opinions

Low Target

$260.00

Mean Target

$300.06

High Target

$342.00

Earnings and Financial Data

Sector

Healthcare

Industry

Diagnostics & Research

Employees

70,000

Earnings & Dividends

Next Earnings

Feb 17, 2026

EPS (Trailing)

$10.18

Dividend Yield

104.0%

Payout Ratio

28.3%

Frequently Asked Questions

Is LH a good stock to buy?

Yes, Labcorp Holdings Inc. (LH) currently has a Buy recommendation from analysts with a price target of $300.06. Given its strong market position in the diagnostics and research sector, the potential for growth is solid.

What is LH’s price target?

Analysts have set a price target of $300.06 for Labcorp, which represents an upside of approximately 9% from the current price of $275.16. This target suggests confidence in the company’s future performance.

Does LH pay a dividend?

Labcorp offers a significant dividend yield of 104.0%, which is anomalously high and warrants further investigation into the sustainability of this payout. It can be attractive for income-focused investors but should be approached with caution.

What is LH’s market cap and P/E ratio?

Labcorp has a market cap of $22.87 billion, with a trailing P/E ratio of 27.03 and a forward P/E of 15.72. These metrics indicate the stock is priced at a premium but also reflects growth expectations in a competitive healthcare landscape.

What has been LH’s stock performance over the last year?

LH has traded within a 52-week range of $209.38 to $293.72, highlighting significant volatility. Currently hovering closer to the high end of this range, it suggests recent strength, but potential market corrections are possible.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.